Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need
Background Regulatory bodies recommend the use of an assay based on the assessment of the endogenous thrombin potential (ETP) for the investigation of the activated protein C resistance (APCr) in the development of steroid contraceptives in women. However, the assays described in the literature are home-made and not standardized regarding the method, the reagents, the reference plasma and the quality controls. In the absence of any commercially available method, we aimed at validating the ETP-based APCr assay. Methods The validation was performed according to regulatory standards. The method targets a 90% inhibition of the ETP in healthy donors in the presence of APC compared to the same condition in the absence of APC. As a large-scale production of a pool of plasma from well-selected healthy donors is impossible, algorithms were applied to a commercial reference plasma to correlate with the selected pool. Results Repeatability and intermediate precision passed the acceptance criteria. The assay demonstrated a curvilinear dose response to protein S and APC concentrations ($ R^{2} $ > 0.99). Analysis of plasma samples from 47 healthy individuals (22 women not taking combined hormonal contraceptives [CHC], and 25 men not Factor V Leiden carriers) confirmed the validity of the test, with a mean inhibition percentage of 90%. Investigations in 15 women taking different contraceptives and in two subjects with Factor V Leiden confirmed the good sensitivity and performance of the assay. Conclusions This validation provides the pharmaceutical industry, the regulatory bodies and physicians with a reproducible, sensitive and validated gold-standard ETP-based APCr assay..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 58(2019), 2 vom: 24. Aug., Seite 294-305 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Douxfils, Jonathan [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
©2019 Walter de Gruyter GmbH, Berlin/Boston |
|---|
| doi: |
10.1515/cclm-2019-0471 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2142196659 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2142196659 | ||
| 003 | DE-627 | ||
| 005 | 20231205151842.0 | ||
| 007 | tu | ||
| 008 | 230811s2019 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2019-0471 |2 doi | |
| 035 | |a (DE-627)OLC2142196659 | ||
| 035 | |a (DE-B1597)cclm-2019-0471-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |a 540 |q VZ |
| 082 | 0 | 4 | |a 540 |a 610 |q VZ |
| 100 | 1 | |a Douxfils, Jonathan |e verfasserin |0 (orcid)0000-0002-7644-5298 |4 aut | |
| 245 | 1 | 0 | |a Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a ©2019 Walter de Gruyter GmbH, Berlin/Boston | ||
| 520 | |a Background Regulatory bodies recommend the use of an assay based on the assessment of the endogenous thrombin potential (ETP) for the investigation of the activated protein C resistance (APCr) in the development of steroid contraceptives in women. However, the assays described in the literature are home-made and not standardized regarding the method, the reagents, the reference plasma and the quality controls. In the absence of any commercially available method, we aimed at validating the ETP-based APCr assay. Methods The validation was performed according to regulatory standards. The method targets a 90% inhibition of the ETP in healthy donors in the presence of APC compared to the same condition in the absence of APC. As a large-scale production of a pool of plasma from well-selected healthy donors is impossible, algorithms were applied to a commercial reference plasma to correlate with the selected pool. Results Repeatability and intermediate precision passed the acceptance criteria. The assay demonstrated a curvilinear dose response to protein S and APC concentrations ($ R^{2} $ > 0.99). Analysis of plasma samples from 47 healthy individuals (22 women not taking combined hormonal contraceptives [CHC], and 25 men not Factor V Leiden carriers) confirmed the validity of the test, with a mean inhibition percentage of 90%. Investigations in 15 women taking different contraceptives and in two subjects with Factor V Leiden confirmed the good sensitivity and performance of the assay. Conclusions This validation provides the pharmaceutical industry, the regulatory bodies and physicians with a reproducible, sensitive and validated gold-standard ETP-based APCr assay. | ||
| 700 | 1 | |a Morimont, Laure |0 (orcid)0000-0001-9195-304X |4 aut | |
| 700 | 1 | |a Delvigne, Anne-Sophie |4 aut | |
| 700 | 1 | |a Devel, Philippe |4 aut | |
| 700 | 1 | |a Masereel, Bernard |4 aut | |
| 700 | 1 | |a Haguet, Hélène |4 aut | |
| 700 | 1 | |a Bouvy, Céline |4 aut | |
| 700 | 1 | |a Dogné, Jean-Michel |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d De Gruyter, 1998 |g 58(2019), 2 vom: 24. Aug., Seite 294-305 |w (DE-627)240770250 |w (DE-600)1418007-8 |w (DE-576)064883795 |x 1434-6621 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2019 |g number:2 |g day:24 |g month:08 |g pages:294-305 |
| 856 | 4 | 1 | |u https://doi.org/10.1515/cclm-2019-0471 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4277 | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2019 |e 2 |b 24 |c 08 |h 294-305 | ||